Gene Editing Service

Our gene editing platform is based on the CRISPR/Cas9 system and is at the forefront of global research in immune cell engineering, particularly in the development of PD-1 knockout CAR-T cells and universal CAR-T therapies. We are among the first teams worldwide to initiate related clinical trials.

For the first time, PD-1 knockout CAR-T cells have been successfully applied in the treatment of multiple solid tumors, including non-small cell lung cancer, esophageal cancer, and breast cancer.

These pioneering results have been recognized by the European Society for Medical Oncology (ESMO) and published in the leading oncology journal Annals of Oncology. In addition, associated invention patents have been granted, further validating the platform’s innovation and clinical impact.